Hebei Changshan Biochemical Pharmaceutical Co., Ltd. Class A

Hebei Changshan Biochemical Pharmaceutical Co., Ltd. Class A

SSZSE:300255
17.39
CNY
-0.43
(-2.41%)
-0.39EPS
21.08BMarket Cap

Total Valuation

CNY

As of September 30, 2026, Hebei Changshan Biochemical Pharmaceutical Co., Ltd. Class A carries a market capitalization of 21.08B, placing it among publicly traded companies globally. Its enterprise value stands at 23.56B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap21.08B
Enterprise Value23.56B

Share Statistics

As of September 30, 2026, Hebei Changshan Biochemical Pharmaceutical Co., Ltd. Class A has 919.06M shares outstanding.

Shares Outstanding919.06M

Valuation Ratios

These figures are as of September 30, 2026. The price-to-sales ratio is 22.65, and the price-to-book ratio stands at 18.07.

PS Ratio22.65
PB Ratio18.07
P/TBV Ratio63.10

Enterprise Valuation

These figures are as of September 30, 2026. The EV/Sales ratio of 25.33 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 23.56B versus a market cap of 21.08B, with the gap driven by net debt and cash on the balance sheet.

EV / Sales25.33

Financial Position

As of September 30, 2026, Hebei Changshan Biochemical Pharmaceutical Co., Ltd. Class A maintains a current ratio of 0.67, meaning it holds 0.7x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 231.29, indicating elevated leverage, while an interest coverage ratio of -3.19 demonstrates limited ability to service its debt obligations.

Current Ratio0.67
Quick Ratio0.03
Debt / Equity231.29
Debt / EBITDA-7.76
Interest Coverage-3.19

Financial Efficiency

CNY

Over the twelve months ended September 30, 2026, Hebei Changshan Biochemical Pharmaceutical Co., Ltd. Class A posted a negative return on equity (ROE) of -26.00, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -7.94, reflecting losses generated across the asset base. The company generates approximately 779,127.88 in revenue per employee across its workforce of 1,194.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 0.64 indicates how many times Hebei Changshan Biochemical Pharmaceutical Co., Ltd. Class A sells and replaces its inventory over a year, a key working capital efficiency ratio.

Return on Equity (ROE)-26.00
Return on Assets (ROA)-7.94
Revenue Per Employee779,127.88
Employee Count1,194.00
Inventory Turnover0.64

Taxes

CNY

Over the twelve months ended September 30, 2026, Hebei Changshan Biochemical Pharmaceutical Co., Ltd. Class A recorded 16.35M in income tax expense. The company reported a pretax loss of -340.28M and -350.97M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

Income Tax16.35M

Stock Price Statistics

CNY

As of the close on November 17, 2026, Hebei Changshan Biochemical Pharmaceutical Co., Ltd. Class A's stock has declined approximately 70.27% over the past 52 weeks. The 50-day moving average sits at 21.17, while the 200-day moving average is 33.01.

52-Week Price Change-70.27%
50-Day Moving Average21.17
200-Day Moving Average33.01

Income Statement

CNY

Over the twelve months ended September 30, 2026, Hebei Changshan Biochemical Pharmaceutical Co., Ltd. Class A generated 930.28M in revenue and converted that into -350.97M in net income, yielding earnings per share of -0.39. EBITDA reached -334.27M, while operating income came in at -40.40M.

Revenue930.28M
Gross Profit189.48M
Operating Income-40.40M
Pretax Income-340.28M
Net Income-350.97M
EBITDA-334.27M
EBIT-334.27M
Earnings Per Share (EPS)-0.39

Balance Sheet

CNY

As of September 30, 2026, Hebei Changshan Biochemical Pharmaceutical Co., Ltd. Class A holds 72.08M in cash and equivalents against 2.60B in total debt, resulting in a net debt position of 2.13B. Total book value stands at 1.17B, with working capital of -794.02M providing operational flexibility.

Cash & Cash Equivalents72.08M
Total Debt2.60B
Net Debt2.13B
Equity (Book Value)1.17B
Book Value Per Share1.27
Working Capital-794.02M

Cash Flow

CNY

These figures cover the twelve months ended September 30, 2026.

Capital Expenditures-131.06M

Margins

Over the twelve months ended September 30, 2026, Hebei Changshan Biochemical Pharmaceutical Co., Ltd. Class A posted a gross margin of 20.37, reflecting its pricing power and cost economics. The operating margin of -4.34 and net profit margin of -37.73 provide insight into operational efficiency.

Gross Margin20.37
Operating Margin-4.34
Pretax Margin-36.58
Profit Margin-37.73
EBITDA Margin-35.93

Dividends & Yields

CNY

Over the twelve months ended September 30, 2026, Hebei Changshan Biochemical Pharmaceutical Co., Ltd. Class A paid dividends of 0.13 per share. The dividend payout ratio of -32.40 is negative because earnings are negative, so the dividend is being paid out of something other than profits, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Total shareholder yield reaches 0.07, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Hebei Changshan Biochemical Pharmaceutical Co., Ltd. Class A shareholders.

Dividend Per Share0.13
Payout Ratio-32.40
Shareholder Yield0.07

Stock Splits

Hebei Changshan Biochemical Pharmaceutical Co., Ltd. Class A's most recent stock split took place on April 20, 2016 with a 5:9 split ratio.

Last Split Date4/20/2016
Split Ratio5:9

Scores

As of September 30, 2026, Hebei Changshan Biochemical Pharmaceutical Co., Ltd. Class A has an Altman Z-Score of 3.79, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score3.79